Bellafill Marks Distribution of 1 Million Syringes

At the close of 2021, Suneva Medical, Inc. says, more than one million syringes of Bellafill have been distributed. Suneva's five-year, filler for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheeks has been available for aesthetic use since 2007.

"The distribution of Bellafill's millionth syringe is an extraordinary milestone for believers like me at Suneva, but what's more important to us is the improvement in self-image for the countless patients who have benefited from this product," says Pat Altavilla, Chief Executive Officer of Suneva. "Bellafill's popularity has grown in recent years, as there are a growing number of patients who are looking for longer-term replacements to shorter-acting fillers, which typically last roughly one to two years. Bellafill can address this growing patient demand and energize the treatment-related needle and budget fatigue many aesthetic patients are likely to feel."

"Bellafill has been revolutionary for both my patients and practice," says Dr. Jason Rupeka, at Youthology Medspa in Warren, OH. "Bellafill is a game changing product that has differentiated myself from other aesthetic providers. By offering my patients instant volume results along with future endogenous collagen production, I've been able to serve their immediate aesthetic needs that will only improve over time. Bellafill provides an innovative alternative for patients who had grown tired of the redundancy and cost of other HA filler treatments."

Suneva Medical and Viveon Health Acquisition Corp. last month announced they had entered into a definitive merger agreement. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE American under the symbol RNEW.